Please Download the latest version of Adobe Flash Player.

 

ABOUT US

Our Team

Participate in our research
News Releases

Terms & Conditions of Use

 
 
 
 
   
   

FOR IMMEDIATE RELEASE
Contact: Ronald Trahan, APR, Ronald Trahan Associates Inc.
508-359-4005, x108

Pico-Tesla expands Phase III pivotal clinical trial of Magneceutical® Therapy for Parkinson’s disease

Three Principal Investigators added, in Denver and Tampa

“We are making great progress toward establishing the clinical potential of Magneceutical® Therapy for Parkinson’s patients.”
-Allen Braswell, CEO, Pico-Tesla

LITTLETON, Colo., Jan. 4, 2011 —Pico-Tesla, The Magneceutical® Company, announced today that it has expanded its ongoing Phase III pivotal clinical trial by adding three Principal Investigators, including two university-affiliated clinicians: one in Denver; and one in Tampa. In addition, Pico-Tesla announced that enrollment is approaching 50% of the patients required for this pivotal clinical trial.

“We are making great progress toward establishing the clinical potential of Magneceutical® Therapy for Parkinson’s patients,” said Allen Braswell, CEO of Pico-Tesla. “We now have six Principal Investigators participating in our pivotal trial in Parkinson’s disease, and all three of our clinical sites are enrolling patients.”

The purpose of the ongoing Phase III pivotal clinical trial is to demonstrate the efficacy of Magneceutical® Therapy as an adjunctive therapy to improving aspects of health and quality of life that are relevant to patients with Parkinson's disease. Pico-Tesla intends to submit the Phase III data and analysis via a 510(k) de novo application to obtain FDA clearance to sell the device in the United States. The Phase III clinical trial was designed by principal investigator Rajeev Kumar, M.D., medical director of the Colorado Neurological Institute Movement Disorder Center, Englewood, Colo.

Pico-Tesla’s Magneceutical® Therapy involves the use of an extremely low-level electromagnetic field (EMF) applied by a specially designed device—the Resonator™, invented by Dr. Jerry I. Jacobson, along with proprietary therapeutic protocols—and is currently in clinical trials to determine its effectiveness for improving the signs and symptoms of several diseases, including Parkinson’s disease, atrial fibrillation, Alzheimer’s disease, fibromyalgia and osteoarthritis.

Privately held Pico-Tesla Magnetic Therapies is an emerging medical technology company with operations at: 4700 140th Avenue North, Suite #101, Clearwater, FL 33762; and, 27780 Novi Road, Suite 100, Novi, MI 48377 (248) 773-8969.

CAUTION: The Resonator™ device is an Investigational Device limited by federal (or United States) law to investigational use. The Resonator™ device is not for sale, nor is the Magneceutical® Therapy generally available outside of Investigational Review Board (IRB)-approved clinical studies.


 
 

4700 140th Ave. N., Suite 101 • Clearwater, FL 33762 • 727-474-3722

HOME | CONTACT US

 
 

The Resonator™ device is an Investigational Device limited by Federal (or United States)
law to investigational use. The Resonator™ device is not for sale, nor is the Magneceutical®
Therapy generally available outside of Investigational Review Board (IRB) approved clinical studies.